Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study

J Clin Oncol. 2022 Jun 10;40(17):1847-1849. doi: 10.1200/JCO.22.00556. Epub 2022 Apr 29.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Mitogen-Activated Protein Kinases / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Thyroid Neoplasms* / drug therapy
  • Thyroid Neoplasms* / radiotherapy

Substances

  • AZD 6244
  • Benzimidazoles
  • Iodine Radioisotopes
  • Protein Kinase Inhibitors
  • Mitogen-Activated Protein Kinases